Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs
article
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
This study investigated how digesting surfactants in lipidic self-emulsifying formulations affects danazol bioavailability after oral administration in dogs.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Lipid-based formulations of danazol with varying quantities of included surfactant have been examined in vitro and in vivo. Formulations comprising fatty acid ester surfactants were readily hydrolysed during in vitro digestion, although Cremophor RH40 (CrRH) was less effectively hydrolysed than Cremophor EL (CrEL). Formulations comprising high quantities of digestible surfactant also appeared to less effectively prevent danazol precipitation during in vitro evaluation. These trends were replicated in vivo where danazol bioavailability in beagle dogs was higher after oral administration of self-emulsifying formulations employing 55% (w/w) CrRH when compared with CrEL. The oral bioavailability of danazol after administration of drug formulated in surfactant alone, however, was poor. Studies using predispersed and encapsulated formulations of CrRH subsequently suggested that the low bioavailability of the single surfactant formulations reflected poor dispersion. Mixtures of surfactants, improved dispersion and good oral bioavailability of danazol was evident after administration of formulations comprising CrRH and either Pluronic L121 or Gelucire 44-14, in spite of evidence of danazol precipitation during in vitro digestion of the Gelucire formulation. These data suggest that effective dispersion and resistance to precipitation during both dispersion and digestion are key design parameters for lipid-based formulations comprising high proportions of surfactant.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules 1999
- A dynamic in vitro lipolysis model 2001
- Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs 2007
- Absorption of Danazol After Administration to Different Sites of the Gastrointestinal Tract and the Relationship to Single‐ and Double‐Peak Phenomena in the Plasma Profiles 1993
Cited by (4)
- Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs 2013
- Danazol 2022
- <i>In Vivo</i> Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems 2016
- Application of Capmul MCM and caprylic acid for the development of danazol-loaded SEDDS 2014
References (39)
- Absorption of Danazol After Administration to Different Sites of the Gastrointestinal Tract and the Relationship to Single‐ and Double‐Peak Phenomena in the Plasma Profiles via openalex
- A dynamic in vitro lipolysis model via openalex
- Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs via openalex
- Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules via openalex
- doi:10.1002/jps.10554 via openalex
- doi:10.1016/j.ejps.2006.04.016 via openalex
- doi:10.1021/j150668a023 via openalex
- doi:10.1016/0378-5173(85)90081-x via openalex
- doi:10.1016/j.ijpharm.2003.12.028 via openalex
- doi:10.1016/j.ejps.2004.08.003 via openalex
- doi:10.1081/ddc-100000125 via openalex
- doi:10.1016/s0378-5173(97)00325-6 via openalex
- doi:10.1007/s11095-006-9054-x via openalex
- doi:10.1021/j100210a011 via openalex
- doi:10.1016/j.jcis.2006.12.015 via openalex
- doi:10.1080/03639040500215750 via openalex
- W2417194615 via openalex
- W2433102311 via openalex
- doi:10.1016/s0378-5173(98)00054-4 via openalex
- doi:10.1023/a:1015987223407 via openalex
- doi:10.1002/jps.10329 via openalex
- doi:10.1038/nrd2197 via openalex
- doi:10.1021/bi00460a011 via openalex
- doi:10.1016/s0169-409x(96)00489-9 via openalex
- doi:10.1016/s0731-7085(00)00528-8 via openalex
- doi:10.1016/s0022-2275(20)36977-7 via openalex
- doi:10.1016/s0022-2275(20)39696-6 via openalex
- doi:10.1211/0022357021771896 via openalex
- doi:10.1016/j.biopha.2004.02.001 via openalex
- doi:10.1016/s0928-0987(00)00167-6 via openalex
- doi:10.1016/s0378-5173(97)00248-2 via openalex
- doi:10.1016/j.jconrel.2005.10.002 via openalex
- doi:10.1002/1522-2683(200204)23:7/8<1053::aid-elps1053>3.0.co;2-3 via openalex
- doi:10.1016/j.bbalip.2007.02.009 via openalex
- doi:10.1023/a:1015843517762 via openalex
- doi:10.1016/j.ijpharm.2004.08.024 via openalex
- doi:10.1023/a:1015877929381 via openalex
- doi:10.1023/b:pham.0000036914.22132.cc via openalex
- doi:10.1002/jps.20039 via openalex
Cited by (4)
- Danazol 2022
- <i>In Vivo</i> Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems 2016
- Application of Capmul MCM and caprylic acid for the development of danazol-loaded SEDDS 2014
- Evaluation of a Nanoemulsion Formulation Strategy for Oral Bioavailability Enhancement of Danazol in Rats and Dogs 2013
Source provenance
- openalex
- last seen: 2026-05-14T06:08:44.784461+00:00
License: CC0
· commercial use OK